What is Bioprotect?
Founded in 2004 and headquartered in Israel, BioProtect is at the forefront of developing advanced medical technologies. The company manufactures proprietary biodegradable implantable balloon solutions designed to protect organs at risk during radiation oncology treatments. Beyond radiation therapy, these innovative solutions also address other critical surgical needs, positioning BioProtect as a key player in both interventional oncology and general surgical applications. The company's commitment to biodegradable materials aims to enhance patient outcomes by minimizing long-term complications associated with traditional implants.
How much funding has Bioprotect raised?
Bioprotect has raised a total of $30.2M across 3 funding rounds:
Series C
$1.7M
Unspecified
$3.5M
Series D
$25M
Series C (2008): $1.7M with participation from Xenia Venture Capital
Unspecified (2017): $3.5M, investors not publicly disclosed
Series D (2020): $25M supported by Peregrine Ventures, KB Investments, Accelmed Ventures, and Consensus Business Group
Key Investors in Bioprotect
Peregrine Ventures
Peregrine Ventures is dedicated to advancing medical innovation through global strategic investments, focusing on life science companies at various stages of development. The company leverages deep industry knowledge and a synergetic strategy to support portfolio companies in bringing groundbreaking healthcare technologies to market.
Xenia Venture Capital
Xenia Venture Capital is a hi-tech investment company focused on investing in high tech and med tech sectors in Israel, specializing in life science investments. The firm provides comprehensive support, including mentoring, strategic counseling, and fundraising assistance, to its portfolio companies.
KB Investments
KB Investments is an entity involved in the funding rounds of Bioprotect, contributing to the company's capital growth. Specific investment focus areas are not detailed but participation in this round indicates strategic interest in the medical technology sector.
What's next for Bioprotect?
With a history of consistent capital raises, including a significant Series D round in 2020, Bioprotect is well-positioned for its next phase of expansion. The recent major strategic investment suggests a strong validation of the company's technology and market strategy by its backers. This influx of capital is likely to fuel further research and development, enhance manufacturing capabilities, and broaden market penetration, particularly in the competitive global medical device landscape. The company's focus on biodegradable solutions aligns with a growing trend towards patient-centric and minimally invasive medical interventions, indicating a promising trajectory for future growth and innovation.
See full Bioprotect company page
